 Source: Bukhta Yurii Shutterstock.com Sorrento Therapeutics NASDAQ: SRNE stock is getting a boost on Wednesday after the FDA granted it fast-track designation for SP-103. SP-103 is Sorrento Therapeutics non-opioid triple-strength, non-aqueous lidocaine topical system for the treatment of acute LBP. 